The role of bacteria in exacerbations of COPD: A constructive view

Chest

Volumn 118, Issue 1, 2000, Pages 204-209

  Murphy, Timothy F ^a   Sethi, Sanjay ^a   Niederman, Michael S ^b  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Antibiotic therapy; Bacterial bronchitis; Chronic bronchitis; Exacerbation; Immune response; Nontypeable H influenzae; Vaccines

Indexed keywords

ANTIBIOTIC AGENT; VACCINE;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; HAEMOPHILUS INFLUENZAE; HUMAN; META ANALYSIS; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

EID: 0033931145     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.118.1.204     Document Type: Article

References (42)

1. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-776
2. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316-1320
3. Fagon J-Y, Chastre J, Trouillet J-L, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 1990; 142:1004-1008
4. Pela R, Marchesani F, Agostinelli C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: A bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53:3-262
5. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:1498-1505
6. Yi K, Sethi S, Murphy TF. Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis. J Infect Dis 1997; 176:1247-1252
7. Duim B, Vogel L, Puijk W, et al. Fine mapping of outer membrane protein P2 antigenic sites which vary during persistent infection by Haemophilus influenzae. Infect Immun 1996; 64:4673-4679
8. Glynn AA. Antibodies to Haemophilus influenzae in chronic bronchitis. BMJ 1959; 2:911-914
9. Morgan WKC, Wood WH. Antibody response to Haemophilus influenzae in obstructive airway disease. Lancet 1965; 1:1128-1131
10. Ross CAC, McMichael S, Eadie MB. Infective agents and chronic bronchitis. Thorax 1966; 21:461-464
11. Reichek N, Lewin EB, Rhoden DL, et al. Antibody responses to bacterial antigens during exacerbations of chronic bronchitis. Am Rev Respir Dis 1970; 101:238-244
12. Gump DW, Christmas WA, Forsyth BR, et al. Serum and secretory antibodies in patients with chronic bronchitis. Arch Intern Med 1973; 132:847-851
13. Musher DM, Kubitschek KR, Crennan J, et al. Pneumonia and acute febrile tracheobronchitis due to Haemophilus influenzae. Ann Intern Med 1983; 99:444-450
14. Chapman AJ, Musher DM, Jonsson S, et al. Development of bactericidal antibody during Branhamella catarrhalis infection. J Infect Dis 1985; 151:878-882
15. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146:1067-1083
16. Musher DM, Luchi MJ, Watson DA, et al. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: Determination of IgG reponses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990; 161:728-735
17. Rubins JB, Alter M, Loch J, et al. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999; 67: 5979-5984
18. Lottenbach KR, Mink CM, Barenkamp SJ, et al. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 1999; 67:4935-4938
19. Clancy R, Cripps A, Murree-Allen K, et al. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet 1985; 2:1395-1397
20. Tandon MK, Gebski V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Aust NZ J Med 1991; 21:427-432
21. Lehmann D, Coakley KJ, Coakley CA, et al. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. Am Rev Respir Dis 1991; 144:324-330
22. Clancy RL, Cripps AW, Gebski V. Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzae. Med J Aust 1990; 152:413-416
23. Murphy TF, Sethi S. A national strategy for research in chronic obstructive pulmonary disease [letter]. JAMA 1997; 277:1596
24. Thompson AB, Daughton D, Robbins RA, et al. Intraluminal airway inflammation in chronic bronchitis. Am Rev Respir Dis 1989; 140:1527-1537
25. Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med 1995; 152: 1926-1931
26. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150:1646-1652
27. Balbi B, Bason C, Balleari E, et al. Increased bronchoalveolar granulocytes and granulocyte-macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997; 10:846-850
28. Sethi S, Muscarella K, Evans N, et al. Comparison of airway inflammation in acute bacterial and non-bacterial exacerbations of COPD [abstract]. Am J Respir Crit Care Med 1999; 159:A822
29. Karawzjczyk M, Pauksen K, Peterson CG, et al. The differential release of eosinophil granule proteins: Studies on patients with acute bacterial and viral infections. Clin Exp Allergy 1995; 25:713-719
30. Yamashita R, Kitahara H, Kanemitsu T, et al. Eosinophil cationic protein in the sera of patients with Mycoplasma pneumonia. Pediatr Infect Dis J 1994; 13:379-381
31. Lehrer RI, Szklarek D, Barton A, et al. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 1989; 142:4428-4434
32. Olszewska-Pazdrak B, Pazdrak K, Ogra PL, et al. Respiratory syncytial virus-infected pulmonary epithelial cells induce eosinophil degranulation by a CD18-mediated mechanism. J Immunol 1998; 160:4889-4895
33. Sanchez-Borges M, Orozeo A, Di Biagio E, et al. Eosinophilia in early-stage human immunodeficiency virus infection. J Allergy Clin Immunol 1993; 92:494-495
34. Moller LVM, Timens W, Van Der Bij W, et al. Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease. Am J Respir Crit Care Med 1998; 157:950-956
35. Ketterer MR, Shao JQ, Hornick DB, et al. Infection of primary human bronchial epithelial cells by Haemophilus influenzae: Macropinocytosis as a mechanism of airway epithelial cell entry. Infect Immun 1999; 67:4161-4170
36. Niederman MS. COPD: The role of infection. Chest 1997; 112:301S-302S
37. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204
38. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: A meta- analysis. JAMA 1995; 273:957-960
39. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. Chest 1998; 113:1542-1548
40. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116:40-46
41. Grossman R, Mukherjee M, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: The Canadian ciprofloxacin health economic study group. Chest 1998; 113:131-141
42. Destache CJ, Dewan N, O'Donahue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43(suppl):107-113